Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder

Brignone, M.; Diamand, F.; Painchault, C.; Takyar, Shweta

doi:10.1185/03007995.2015.1128404

Cited by 27 publications

(35 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common side effects associated with this drug are nausea, vomiting, and constipation. Vortioxetine is currently studied as a potential therapeutic alternative for patients who fail to respond to SSRIs or SNRIs 31 .…”

Section: Depressionmentioning

confidence: 99%

New drugs in psychiatry: focus on new pharmacological targets

et al. 2017

View full text Add to dashboard Cite

The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer’s disease. All of the compounds considered were recently approved for human use or are in advanced clinical trials. Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine. As for Alzheimer’s disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.

show abstract

Section: Depressionmentioning

confidence: 99%

New drugs in psychiatry: focus on new pharmacological targets

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Vortioxetine is a well-tolerated treatment, with a statistically lower withdrawal rates due to AEs compared with these antidepressants. (14) (15) Vortioxetine has been recently approved by NICE as an option for treating MDE in adults whose condition has responded inadequately to two antidepressants within the current episode. Detail on the process can be found in the NICE technology appraisal guidance for vortioxetine (TA367) and the Evidence Review Group critique in Lomas 2016.…”

Section: )(13)mentioning

confidence: 99%

Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom

Young

Evitt²,

Brignone

et al. 2017

Journal of Affective Disorders

View full text Add to dashboard Cite

show abstract

“…Vortioxetine given orally once daily, to start with an initial dose of 5 mg or 10 mg and can be extended to a maximum of 20 mg, depending on the situation of the case under the fed condition or fasting conditions. 2 There are lots of regulatory challenges to address the regulatory queries on control and carryover by organic impurities in drug substance or drug product. These impurities are sometime genotoxic, hence the proper study of these impurities by the suitably developed analytical method is critical in drug development in today's scenario.…”

Section: Introductionmentioning

confidence: 99%

Separation and Quantification of Structurally Similar Impurities by HPLC Method of Vortioxetine Hydrobromide- An Antidepressant Drug

Landge¹,

Dahale²,

Devadhe³

et al. 2020

ECB

View full text Add to dashboard Cite

A new, specific, and robust normal phase liquid chromatographic (NP-LC) method for the determination of structurally similar impurities (isomers) of Vortioxetine hydrobromide has been developed and validated. An excellent chromatographic resolution between the structurally similar impurities (isomers) and Vortioxetine hydrobromide was achieved on Chiralpak-ADH (250 x 4.6 mm ID), 5 µ column. The mobile phase used of n-hexane, ethanol, diethylamine, and trifluoroacetic acid in the ratio (75:25:0.05:0.05, v/v/v/v) and the flow rate was maintained at 1.0 mLmin-1. UV detection was carried out at 235 nm. The resolution between all positional isomers and Vortioxetine hydrobromide was found not less than 2. An effect of column oven temperature on the resolution was also studied and found to be ≥ 2.0. Three structurally similar impurities (Isomer-1, Isomer-2, and Isomer-3) have been detected in the test sample of Vortioxetine hydrobromide by advanced NP-LC method. Further, these isomeric impurities were characterized by mass spectrometry, 1 H NMR and FT-IR spectral data. The developed method was validated as per ICH guidelines and found to be specific, robust, and selective. The developed NP-LC method was successfully applied to the analysis of drug substance and drug product samples of Vortioxetine hydrobromide.

show abstract

Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder

Cited by 27 publications

References 67 publications

New drugs in psychiatry: focus on new pharmacological targets

New drugs in psychiatry: focus on new pharmacological targets

Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom

Separation and Quantification of Structurally Similar Impurities by HPLC Method of Vortioxetine Hydrobromide- An Antidepressant Drug

Contact Info

Product

Resources

About